Gastrointestinal cancers: new standards of care from landmark trials
Received for publication October 2, 2017
Published online ahead of print March 28, 2018
Correspondence
David H Henry, MD; David.Henry@uphs.upenn.edu;
Daniel G Haller, MD, FACP, FRCP; Daniel.Haller@uphs.upenn.edu
Disclosures The authors report no disclosures/conflicts of interest.
Citation JCSO 2018; 16(2): e117-e122
©2018 Frontline Medical Communications
doi https://doi.org/10.12788/jcso.0377
Listen to the audio here
Submit a paper here
DR HENRY Great data and a small population, but a population in need. That moves us on to pancreatic cancer, and I don’t know if this is happening nationwide, but in my practice, I’m seeing more. These patients tend to present beyond surgery, so they have metastatic or advanced pancreatic cancer. Any comment on where you think this field is going?
DR HALLER We were a bit bereft of new pancreatic cancer studies at ASCO this year. We’re certainly looking more at neoadjuvant therapy for pancreatic cancer, primarily because of ease of administration and the increased ability to tolerate treatments in the preoperative setting. There aren’t many people that get downstaged, but some are. Unfortunately, even in the MSI-high pancreas, which is a small subset, they don’t seem to get as big a bang out of the checkpoint inhibitors as in other tumor sites, so I’m afraid I didn’t come home with much new about this subset of patients.
DR HENRY We’ve covered a nice group of studies and practice-changing new standard-of-care comments from ASCO and other studies. Thank Dr Dan Haller for being with us and commenting. This podcast and discussion are brought to you from
